Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

More measles cases have been reported in Washington state. Officials in Seattle-King County yesterday reported two measles ...

COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN ® ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population ...

Bavarian Nordic produces one of the only vaccines for mpox and its shots are the only ones licensed for the disease in the U.S. and European Union.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Aug 17 (Reuters) - Danish biotech firm Bavarian Nordic , opens new tab said on Saturday it plans to ramp up production of its mpox vaccine and work with international health organisations to ...

The WHO’s declaration of an emergency has caused Bavarian Nordic’s shares to jump over 40%. The company's shares are up 51% since the start of the year, with its market cap at $3.28 billion.

Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. Skip to Main Content.

Bavarian Nordic's vaccine has been used worldwide since 2022, after U.S. and European regulators backed it for use against a different strain of mpox that spread globally in 2022.